Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 14/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 14/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067748 | 1.00 | P2RX3 (0.36) | P2RX3P2RX2NOS3NOS1NOS2 | |
| SCHEMBL25911621 | 0.85 | P2RX3 (0.36) | P2RX3P2RX2NOS3NOS1NOS2 | |
| SCHEMBL30068288 | 0.85 | P2RX3 (0.36) | P2RX3P2RX2NOS3NOS1NOS2 | |
| SCHEMBL31214193 | 0.83 | PIK3CA (0.32) | PIK3CAMAPTCASP1 | |
| SCHEMBL10085335 | 0.82 | KMT2A (0.34) | MAPTCASP1 | |
| SCHEMBL13745097 | 0.79 | PIK3CA (0.35) | P2RX3P2RX2NOS3NOS1NOS2 | |
| SCHEMBL6124109 | 0.78 | PDCD1 (0.38) | — | |
| SCHEMBL9606634 | 0.78 | PIK3CA (0.33) | NOS3NOS1NOS2PIK3CA | |
| SCHEMBL27895438 | 0.78 | PIK3CA (0.33) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL29335014 | 0.77 | NOS3 (0.39) | P2RX3P2RX2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885NOS3 1694/4885 |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885NOS3 1969/4885 |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885NOS3 1969/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | P2RX3 4602/4885P2RX2 4559/4885NOS3 1318/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | P2RX3 3456/4885P2RX2 3446/4885NOS3 4589/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | P2RX3 3943/4885P2RX2 3894/4885NOS3 4072/4885 |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885NOS3 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.